Trial intelligence / Profile preview

Phase 3 randomized double-blind placebo-controlled maintenance study of gilteritinib in FLT3-ITD acute myeloid leukemia in first complete remission

MOH_2017-07-04_000387Phase 3Not yet recruiting

Sponsor

Astellas Pharma

Start

Apr 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1